Feature | HRS | May 16, 2017

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

HRS presentations include data on the S-ICD, Micra, Nanostim, PV isolation, lead extractions and pharma

An electrophysiology EP ablation procedure to treat a heart arrhythmia

May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017 annual meeting May 10-13, in Chicago. The data presented is for the latest in electrophysiology (EP) clinical research, techniques and technologies. These trials were featured at Heart Rhythm 2017 and will be published in the July issue of the Heart Rhythm Journal. 

Late-breaking Studies Presented at HRS 2017:

• The S-ICD Post-market Approval Study

Intra-nasal Etripamil For Conversion Of Paroxysmal Supraventricular Tachycardia (PSVT). Node-1 Trial

A Leadless Pacemaker In The Real-world Setting: The Micra Transcatheter Pacing System Post-approval Registry

• EWOLUTION trial: 1-Year Efficacy and Safety of Left Atrial Appendage Closure with WATCHMAN in Patients with or without Contraindication to Oral Anticoagulation

High Incidence Of Previously Unknown (“Silent”) Atrial Fibrillation In Patients At High Risk For Atrial Fibrillation And Stroke: Primary Results From The REVEAL AF Study

Compliant Endovascular Balloon Reduces the Lethality of Superior Vena Cava Tears During Transvenous Lead Extractions

First-in-man Feasibility Study Of Subcutaneous Defibrillation Utilizing An Integrated Flexible String Shaped Defibrillator

PV Isolation With A Novel Multielectrode Radiofrequency Balloon Catheter That Allows Directionally-tailored Energy Delivery (RADIANCE): A Multicenter First-in-man Experience

• A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU (Apixaban Evaluation Of Interrupted Or Uninterrupted Anticoagulation For Ablation Of Atrial Fibrillation) Trial

• Long Detection Programming In Single Chamber Defibrillators Reduces Unnecessary Therapies And Mortality: The Advance III Trial

• SPECT-guided Left Ventricular Lead Placement For Improved CRT Efficacy: A Randomized Controlled Trial

• Ranolazine in High-Risk ICD Patients (RAID) Trial

• Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment In Subjects With Recurrent Atrial Fibrillation: Results From The Powder AF Multicentre Randomised Trial

• The Nanostim Leadless Pacemaker: Battery Failures and Worldwide Chronic Device Retrieval

 

Other Key Presentations:

VIDEO: Editor's Choice of Most Innovative New Technology at HRS 2017

VIDEO: EP Lead Extraction Strategies, interview with Bruce Wilkoff, M.D.

VIDEO: Current State of Leadless Pacemaker Technology, interview with Vivek Reddy, M.D.

VIDEO: Overview of Subcutaneous ICD Technology

VIDEO: How to Start an Electrophysiology Program

Expert Consensus Released on Catheter, Surgical Ablation of Atrial Fibrillation

Expert Consensus on MRI and Radiation Exposure in Patients With Implantable Cardiac Electronic Devices

Watch the VIDEO "Current State of Atrial Fibrillation Technologies," an interview with Dr. Hugh Calkins.

Watch the VIDEO interview with HRS President Michael Gold, M.D., on latest EP technology trends

 

Link to Heart Rhythm 2018 Late-breaking Studies
 

For more information: www.hrssessions.org


Related Content

News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
News | Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home December 22, 2023
Home
News | Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

Home December 14, 2023
Home
Subscribe Now